These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 34112210)

  • 1. Outcome of L-DEP regimen for treatment of pediatric chronic active Epstein-Barr virus infection.
    Ma H; Zhang L; Wei A; Yang J; Wang D; Zhang Q; Zhao Y; Chen S; Lian H; Zhang L; Zhou C; Qin M; Li Z; Wang T; Zhang R
    Orphanet J Rare Dis; 2021 Jun; 16(1):269. PubMed ID: 34112210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PEG-aspargase and DEP regimen combination therapy for refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.
    Wang J; Wang Y; Wu L; Zhang J; Lai W; Wang Z
    J Hematol Oncol; 2016 Sep; 9(1):84. PubMed ID: 27613189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults and adolescents-a life-threatening disease: analysis of 133 cases from a single center.
    Lai W; Wang Y; Wang J; Wu L; Jin Z; Wang Z
    Hematology; 2018 Dec; 23(10):810-816. PubMed ID: 29957156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. L-DEP regimen salvage therapy for paediatric patients with refractory Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis.
    Zhao Y; Li Z; Zhang L; Lian H; Ma H; Wang D; Zhao X; Zhang Q; Wang T; Zhang R
    Br J Haematol; 2020 Nov; 191(3):453-459. PubMed ID: 32525580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical analysis of chronic active EBV infection with coronary artery dilatation and a matched case-control study.
    Wei A; Ma H; Zhang L; Li Z; Guan Y; Zhang Q; Wang D; Lian H; Zhang R; Wang T
    Orphanet J Rare Dis; 2021 Jan; 16(1):50. PubMed ID: 33509232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [L-DEP regimen salvage therapy for refractory primary hemophagocytic lymphohistiocytosis triggered by Epstein-Barr virus infection in 4 children].
    Zhao YZ; Ma HH; Lian HY; Wang D; Wang TY; Zhang R
    Zhonghua Er Ke Za Zhi; 2024 May; 62(5):467-472. PubMed ID: 38623016
    [No Abstract]   [Full Text] [Related]  

  • 7. L-DEP regimen is effective as an initial therapy for adult EBV-HLH.
    Chen L; Wang J; Wang Z
    Ann Hematol; 2022 Nov; 101(11):2461-2470. PubMed ID: 36094533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haploidentical hematopoietic stem cell transplantation for pediatric patients with chronic active Epstein-Barr virus infection: a retrospective analysis of a single center.
    Luo YH; Yang J; Wei A; Zhu GH; Wang B; Zhang R; Jia CG; Yan Y; Wang K; Li S; Zhou X; Qin MQ; Wang TY
    World J Pediatr; 2021 Dec; 17(6):626-636. PubMed ID: 34739695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Ruxolitinib combined with liposomal doxorubicin, etoposide, methylprednisolone+/-PEG-asparaginase in treatment of relapsed/refractory pediatric hemophagocytic lymphohistiocytosis].
    Wei A; Ma HH; Zhang LP; Lian HY; Du JY; Wang D; Cui L; Ou WX; Zhao YZ; Zhao XX; Zhang L; Li ZG; Wang TY; Zhang R
    Zhonghua Yi Xue Za Zhi; 2022 Jul; 102(28):2167-2172. PubMed ID: 35872580
    [No Abstract]   [Full Text] [Related]  

  • 10. Outcomes of programmed death protein-1 inhibitors treatment of chronic active Epstein Barr virus infection: A single center retrospective analysis.
    Ma Y; Zhang P; Bao Y; Luo H; Wang J; Huang L; Zheng M
    Front Immunol; 2023; 14():1093719. PubMed ID: 36969150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical utility of measuring Epstein-Barr virus-specific cell-mediated immunity after HSCT in addition to virological monitoring: results from a prospective study.
    Chiereghin A; Piccirilli G; Belotti T; Prete A; Bertuzzi C; Gibertoni D; Gabrielli L; Turello G; Borgatti EC; Barbato F; Sessa M; Arpinati M; Bonifazi F; Lazzarotto T
    Med Microbiol Immunol; 2019 Dec; 208(6):825-834. PubMed ID: 31289930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon alpha as antiviral therapy in chronic active Epstein-Barr virus disease with interstitial pneumonia - case report.
    Roliński J; Grywalska E; Pyzik A; Dzik M; Opoka-Winiarska V; Surdacka A; Maj M; Burdan F; Pirożyński M; Grabarczyk P; Starosławska E
    BMC Infect Dis; 2018 Apr; 18(1):190. PubMed ID: 29678144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic hematopoietic stem cell transplantation with the modified myeloablative conditioning regimen for children with chronic active Epstein-Barr virus infection.
    Luo Y; Wei A; Wang B; Zhu G; Zhang R; Jia C; Yan Y; Zhou X; Yang J; Qin M; Wang T
    Pediatr Investig; 2022 Dec; 6(4):250-259. PubMed ID: 36582272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Monitoring of early Epstein-Barr virus reactivation and preemptive therapy after allogeneic hematopoietic stem cell transplantation].
    Lu Y; Wu T; Cao XY; Wang JB; Sun Y; Zhao YL; DA WM; Ji SQ; Tong CR; Lu DP
    Zhonghua Nei Ke Za Zhi; 2011 May; 50(5):383-7. PubMed ID: 21624219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The time-dependent effects of early-onset Epstein-Barr viremia on adult acute leukemia patients following allo-HSCT with ATG-containing MAC regimen.
    Ke P; Zhang X; Liu S; Zhu Q; Ma X; Chen F; Tang X; Han Y; Fu Z; Chen S; Wu D; Qiu H; Zhou J; Bao X
    Ann Hematol; 2021 Jul; 100(7):1879-1889. PubMed ID: 33885923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic hematopoietic stem cell transplantation for Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disease in Japan.
    Sato E; Ohga S; Kuroda H; Yoshiba F; Nishimura M; Nagasawa M; Inoue M; Kawa K
    Am J Hematol; 2008 Sep; 83(9):721-7. PubMed ID: 18626884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HLA-mismatched GPBSC infusion therapy in refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis: an observational study from a single center.
    Song Y; Wang J; Wang Y; Wang Z
    Stem Cell Res Ther; 2020 Jul; 11(1):265. PubMed ID: 32611452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of six different specimen types for Epstein-Barr viral load quantification in peripheral blood of pediatric patients after heart transplantation or after allogeneic hematopoietic stem cell transplantation.
    Ruf S; Behnke-Hall K; Gruhn B; Bauer J; Horn M; Beck J; Reiter A; Wagner HJ
    J Clin Virol; 2012 Mar; 53(3):186-94. PubMed ID: 22182950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical and pathological features of 13 children with Epstein-Barr virus-positive lymphoproliferative disease].
    Chen TM; Deng ZJ; Hu B; Hu HL; Chen HY; Li SY; Liu G
    Zhonghua Er Ke Za Zhi; 2018 Oct; 56(10):759-764. PubMed ID: 30293280
    [No Abstract]   [Full Text] [Related]  

  • 20. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
    Chiereghin A; Prete A; Belotti T; Gibertoni D; Piccirilli G; Gabrielli L; Pession A; Lazzarotto T
    Transpl Infect Dis; 2016 Feb; 18(1):44-54. PubMed ID: 26574232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.